Literature DB >> 15086418

Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.

Mary Mathias1, Kate Khair, Ian Hann, Ri Liesner.   

Abstract

We report the use of rituximab (Genentech, San Francisco, CA, USA) in two children with severe haemophilia with inhibitors to factors VIII and IX, which failed to respond to conventional immune tolerance therapy. The treatment was well tolerated by both children. The child with haemophilia B had no clinical improvement or fall in CD19 and he is currently being treated with recombinant activated factor VII (NovoSeven, Novo Nordisk, Denmark) for bleeding episodes. The child with haemophilia A had a good clinical response with a negative inhibitor assay at 11 months follow-up.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15086418     DOI： 10.1111/j.1365-2141.2004.04916.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Treatment with rituximab in benign and malignant hematologic disorders in children.

Authors:  Lisa B Giulino; James B Bussel; Ellis J Neufeld
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

Review 2.  Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.

Authors:  Carol H Miao
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

3.  Ectopic platelet-delivered factor (F) VIII for the treatment of Hemophilia A: Plasma and platelet FVIII, is it all the same?

Authors:  Teshell K Greene; Michele P Lambert; Mortimer Poncz
Journal:  J Genet Syndr Gene Ther       Date:  2011-11-12

4.  In vivo efficacy of platelet-delivered, high specific activity factor VIII variants.

Authors:  Teshell K Greene; Cheng Wang; Jessica D Hirsch; Li Zhai; Jamie Gewirtz; Michael A Thornton; Hongzhi Z Miao; Steven W Pipe; Randal J Kaufman; Rodney M Camire; Valder R Arruda; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2010-09-17       Impact factor: 22.113

Review 5.  Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Authors:  Zera Tellier; Marie-Hélène André; Benoît Polack
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 6.  Management of factor VIII inhibitors.

Authors:  Donna M Dimichele
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

7.  Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.

Authors:  C Leissinger; C D Josephson; S Granger; B A Konkle; R Kruse-Jarres; M V Ragni; J M Journeycake; L Valentino; N S Key; J C Gill; K R McCrae; E J Neufeld; C Manno; L Raffini; K Saxena; M Torres; V Marder; C M Bennett; S F Assmann
Journal:  Thromb Haemost       Date:  2014-06-12       Impact factor: 5.249

8.  Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.

Authors:  Patricia E Zerra; Courtney Cox; W Hunter Baldwin; Seema R Patel; Connie M Arthur; Pete Lollar; Shannon L Meeks; Sean R Stowell
Journal:  Blood       Date:  2017-10-04       Impact factor: 22.113

9.  Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice.

Authors:  Andrea Annoni; Alessio Cantore; Patrizia Della Valle; Kevin Goudy; Mahzad Akbarpour; Fabio Russo; Sara Bartolaccini; Armando D'Angelo; Maria Grazia Roncarolo; Luigi Naldini
Journal:  EMBO Mol Med       Date:  2013-09-16       Impact factor: 12.137

10.  A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy.

Authors:  Alex C Chen; Xiaohe Cai; Chong Li; Liliane Khoryati; Marc A Gavin; Carol H Miao
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.